While ultrasound has been for decades to image organs, check blood flow, and monitor the development of fetuses, new study tests the use of these pulsed sound waves to direct and focus cancer drug therapies. The study is being conducted by a Norwegian biotech company called Phoenix Solutions AS in collaboration with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Cell Phone Radiation and Cancer - Unveiling the Link
Scared after hearing all the harmful effects of cell phone use? Read on to find more about what cell phone radiation actually does and how you can cut down on the exposure.
Advertisement
‘Ultrasound based approach may help target cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.’
Tweet it Now
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
![Screening for Breast Cancer with Clinical Breast Examination]( "Screening for Breast Cancer with Clinical Breast Examination")
Clinical breast examination is a simple and inexpensive method of detecting breast cancer especially in women who do not have access to mammography.
"We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program," said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease -- nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
"We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising," said Dr. Haiyong Han, a Professor in TGen's Molecular Medicine Division and head of the Basic Research Unit in TGen's Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, "We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development."
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
Source: Eurekalert
Screening for Breast Cancer with Clinical Breast Examination
Clinical breast examination is a simple and inexpensive method of detecting breast cancer especially in women who do not have access to mammography.
Advertisement
"We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program," said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease -- nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
"We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising," said Dr. Haiyong Han, a Professor in TGen's Molecular Medicine Division and head of the Basic Research Unit in TGen's Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, "We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development."
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
Source: Eurekalert
Skin Cancer
Skin cancer is an abnormal growth of skin cells. It can develop due to a continuous exposure to sun over the years.
Advertisement
 Small Intestinal CancerLearn all about the early signs, symptoms, prevention and treatment of small intestine cancer. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Cerebrospinal fluid (CSF) leaks are detected in approximately 1-3% of adults who have experienced a traumatic brain injury.
The optogenetic activation of hippocampal astrocytes can be viewed as a novel therapeutic avenue for addressing Alzheimer's disease.
In Alzheimer's disease condition, the control and adjustment of ABCA7 levels in response to inflammation and the decrease in the availability of cholesterol.
Atopic dermatitis (AD) and inflammatory bowel disease (IBD) can lead to alterations in the microbiome, and disruptions in the skin and gut barrier.
Gaining insights into mortality risks among vitiligo patients will enhance patient counseling, healthcare monitoring, and overall patient management strategies.
